Prognostic and Predictive Value of the Tumor-Stroma Ratio in STAGE II Colon Cancer
Prognostic and Predictive Value of the Tumor-Stroma Ratio in STAGE II Colon Cancer
Author Info
Armin Gerger Austrian Breast and Colorectal Cancer Study Group (ABCSG) Evelyne Bareck Gabi W. van Pelt Hans Rabl Hans Gelderblom Klaus Geissler Martin Filipits Michael Gnant Peter Götzinger Renate Schaberl-Moser Richard Greil Rob A. Tollenaar Stefan W. de Vroome Stéphanie M. Zunder Thomas Bachleitner-Hofmann Wilma E. Mesker Wolfgang Hilbe
Corresponding Author
Wilma E. MeskerDepartment of Surgery, Leiden University Medical Centre, Leiden, The Netherlands
A B S T R A C T
Background: Tumor-stroma ratio (TSR) is an independent prognosticator in colon cancer. Objective: We set out to investigate the predictive power, as well as to validate the prognostic power of TSR in stage II colon cancer patients. Better identification of patients who could benefit from adjuvant chemotherapy remains an important issue in stage II disease. Methods: TSR was microscopically determined on haematoxylin and eosin-stained primary tumor tissue slides of 212 patients who received either adjuvant chemotherapy or surveillance after curative resection in a prospective randomized clinical trial (ABCSG-91). Results: Stroma-high tumors were associated with significantly more cancer-related death ((CaDeath) HR 2.30, 95% CI 1.05−5.03; p=0.037) and significantly shorter distant recurrence-free survival ((DRFS) HR 2.32, 95% CI 1.10−4.87; p=0.027) compared to stroma-low tumors. Backward multivariate Cox-regression analysis demonstrated TSR as an independent prognosticator for DRFS (p=0.027) and CaDeath (p=0.031). TSR did not validate as a predictive biomarker; CaDeath (HR 0.87, 95% CI 0.18−4.17; p=0.87), DRFS (HR 0.76, 95% CI 0.17−3.36; p=0.71) and OS (HR 0.96, 95% CI 0.29−3.21; p=0.95) for the type of chemotherapy given in ABCSG-91. Conclusions: TSR, an easily applicable and inexpensive observer-based method, is an independent predictor of poor prognosis in stage II colon cancer. Predictive value for adjuvant 5-FU/leucovorin could not be demonstrated.
Article Info
Article Type
Research ArticlePublication history
Received: Mon 13, Apr 2020Accepted: Tue 28, Apr 2020
Published: Thu 30, Apr 2020
Copyright
© 2023 Wilma E. Mesker. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.DOI: 10.31487/j.COR.2020.04.12